Müller-Bühl Uwe, Laux Gunter, Szecsenyi Joachim
Department of General Practice and Health Services Research, University Hospital, University of Heidelberg, Voßstrasse 2, Geb. 37, 69115 Heidelberg, Germany.
Int J Vasc Med. 2011;2011:316496. doi: 10.1155/2011/316496. Epub 2011 Jun 26.
Background. The aim of the study was to determine the secondary preventive medical supply of patients with peripheral arterial disease (PAD) in German primary care. Methods and Results. A population-based case control study was conducted using electronic medical records of patients extracted from the CONTENT primary care database of Heidelberg, Germany, between April 2007 and March 2010. The prescription rates of cardiovascular medication among symptomatic PAD patients were analysed by means of the ATC classification and compared with those of patients with cardiovascular disease (CVD). 479 cases with PAD and 958 sex- and age-matched control CVD patients were identified. PAD patients showed significantly lower prescription rates for cardiac agents (21.7% versus 37%), β-blockers (50.1% versus. 66.2%), and lipid-lowering agents (50.3% versus 55.9%) compared to CVD patients. In contrast, significantly more prescriptions of antidiabetic agents (28.2% versus 20.3%), particularly insulin and analogues (12.5% versus 8%), and calcium channel blockers (29.2% versus 24.3%) were found in PAD patients. Low-dose aspirin use among both PAD and CVD patients was underestimated, as it is available without a prescription. Conclusions. Optimal pharmacotherapeutical care of patients with PAD requires more intensive cardioprotective medication in primary care settings.
背景。本研究的目的是确定德国初级保健中周围动脉疾病(PAD)患者的二级预防医疗供应情况。方法与结果。采用从德国海德堡CONTENT初级保健数据库中提取的患者电子病历,于2007年4月至2010年3月进行了一项基于人群的病例对照研究。通过解剖学治疗学化学(ATC)分类分析有症状PAD患者心血管药物的处方率,并与心血管疾病(CVD)患者的处方率进行比较。共识别出479例PAD患者和958例性别及年龄匹配的对照CVD患者。与CVD患者相比,PAD患者的心脏药物处方率(21.7%对37%)、β受体阻滞剂处方率(50.1%对66.2%)和降脂药物处方率(50.3%对55.9%)显著较低。相比之下,在PAD患者中发现抗糖尿病药物的处方明显更多(28.2%对20.3%),尤其是胰岛素及其类似物(12.5%对8%),以及钙通道阻滞剂(29.2%对24.3%)。由于低剂量阿司匹林无需处方即可获得,因此PAD和CVD患者中其使用情况被低估。结论。对PAD患者进行最佳药物治疗需要在初级保健环境中加强心脏保护药物治疗。